VLCC, a leader in beauty and wellness industry in India, today
announced that it has signed a license agreement with theCentral Marine
Fisheries Research Institute (CMFRI), the premier Kochi-based marine
research establishment of the Indian Council of Agricultural Research (ICAR),
Government of India, for exclusive rights to manufacture, market and use Cadalmin
Antihypercholesterolemic (Cadalmin ACe) extract. This marine algae
based nutraceutical product has been developed after years of intensive research
by CMFRI and has been found to be effective in combating dyslipidemia and
obesity.
As per CMFRI’s research, Cadalmin Ace provides a unique blend of
100 per cent natural marine bioactive ingredients from selected seaweeds known
for their extraordinary medicinal properties, with an eco-friendly ‘green’
technology.VLCC will have the exclusive rights to manufacture and market
Cadalmin Ace nutraceutical. VLCC has GMP certified manufacturing facilities in
India and Singapore.
This nutraceuticalthat has been developed by CMFRI after years
of intensive research and testing.The pre-clinical trial showed no test
substance-related general organ or systemic toxicity following long term oral
administration of CadalminT ACe. VLCC will be working closely with
the CMFRI to source relevant seaweed and manufacture the product as per CMFRI
developed technology.
Speaking on the signing of the agreement, Vandana
Luthra, Founder, VLCC said, “We are excited that we have received the
CMFRI license for Cadalmin ACe. High cholesterol and obesity are lifestyle
related diseases that are becoming increasingly common across age groups and
lead to many other health problems, including blood pressure, diabetes, and
cardiovascular ailments. VLCC has been committed to fighting obesity for
decades and Cadalmin ACe, with its high level of efficacy and no side effects,
will be instrumental in our next stage of fight against obesity. We are
confident that it will be well received by consumers in India and across other
countries in the world. ”
Dr.A Gopalakrishnan, Director, CMFRI, said “Cadalmin Antihypercholesterolemic
extract is the fourth in the series of the nutraceutical products developed by
the CMFRI. Bioactive pharmacophore leads from seaweeds were used to prepare the
Cadalmin TMAce nutraceutical. It does not have any side
effects as established by detailed preclinical trials and is a natural remedy
of obesity and dyslipidemia.”
Dyslipidemia is
an abnormal amount of lipids (e.g.,triglycerides, cholesterol and/or fat
phospholipids) in the blood.
VLCC has been spreading awareness on anti-obesity and healthy
living across the world, for decades. Through its extensive of products and
services, it has been transforming lives and helping its customers to get fit
and feel more confident. VLCC’s Anti-Obesity campaign has evolved into a larger
movement, which has gained momentum as a public health campaign. The brand had
also established Orange Pledge,where people could enroll for their commitment
to the cause. In November 2016, VLCC celebrated 15 years of Anti-Obesity Day
with the ‘Standup India’ campaign – a public awareness initiative that
encourages people to be more active in their daily lives through the simple act
of standing up.
No comments:
Post a Comment